BACKGROUND: Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated the long-term outcomes of these transplants and aimed to identify potential prognostic factors. DESIGN AND METHODS: In this observational study we analyzed all first autologous hematopoietic stem cell transplants for autoimmune diseases reported to the European Group for Blood and Marrow Transplantation (EBMT) registry between 1996-2007. The primary end-points for analysis were overall survival, progression-free survival and transplant-related mortality at 100 days. RESULTS: Nine hundred patients with autoimmune diseases (64% female; median age, 35 years) who underwent a first autologous hematopoietic stem cell transplant were included. The main diseases were multiple sclerosis (n=345), systemic sclerosis (n=175), systemic lupus erythematosus (n=85), rheumatoid arthritis (n=89), juvenile arthritis (n=65), and hematologic immune cytopenia (n=37). Among all patients, the 5-year survival was 85% and the progression-free survival 43%, although the rates varied widely according to the type of autoimmune disease. By multivariate analysis, the 100-day transplant-related mortality was associated with the transplant centers' experience (P=0.003) and type of autoimmune disease (P=0.03). No significant influence of transplant technique was identified. Age less than 35 years (P=0.004), transplantation after 2000 (P=0.0015) and diagnosis (P=0.0007) were associated with progression-free survival. CONCLUSIONS: This largest cohort studied worldwide shows that autologous hematopoietic stem cell transplantation can induce sustained remissions for more than 5 years in patients with severe autoimmune diseases refractory to conventional therapy. The type of autoimmune disease, rather than transplant technique, was the most relevant determinant of outcome. Results improved with time and were associated with the transplant centers' experience. These data support ongoing and planned phase III trials to evaluate the place of autologous hematopoietic stem cell transplantation in the treatment strategy for severe autoimmune diseases.
BACKGROUND: Autologous hematopoietic stem cell transplantation has been used since 1996 for the treatment of severe autoimmune diseases refractory to approved therapies. We evaluated the long-term outcomes of these transplants and aimed to identify potential prognostic factors. DESIGN AND METHODS: In this observational study we analyzed all first autologous hematopoietic stem cell transplants for autoimmune diseases reported to the European Group for Blood and Marrow Transplantation (EBMT) registry between 1996-2007. The primary end-points for analysis were overall survival, progression-free survival and transplant-related mortality at 100 days. RESULTS: Nine hundred patients with autoimmune diseases (64% female; median age, 35 years) who underwent a first autologous hematopoietic stem cell transplant were included. The main diseases were multiple sclerosis (n=345), systemic sclerosis (n=175), systemic lupus erythematosus (n=85), rheumatoid arthritis (n=89), juvenile arthritis (n=65), and hematologic immune cytopenia (n=37). Among all patients, the 5-year survival was 85% and the progression-free survival 43%, although the rates varied widely according to the type of autoimmune disease. By multivariate analysis, the 100-day transplant-related mortality was associated with the transplant centers' experience (P=0.003) and type of autoimmune disease (P=0.03). No significant influence of transplant technique was identified. Age less than 35 years (P=0.004), transplantation after 2000 (P=0.0015) and diagnosis (P=0.0007) were associated with progression-free survival. CONCLUSIONS: This largest cohort studied worldwide shows that autologous hematopoietic stem cell transplantation can induce sustained remissions for more than 5 years in patients with severe autoimmune diseases refractory to conventional therapy. The type of autoimmune disease, rather than transplant technique, was the most relevant determinant of outcome. Results improved with time and were associated with the transplant centers' experience. These data support ongoing and planned phase III trials to evaluate the place of autologous hematopoietic stem cell transplantation in the treatment strategy for severe autoimmune diseases.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Richard A Nash; Peter A McSweeney; Leslie J Crofford; Muneer Abidi; Chien-Shing Chen; J David Godwin; Theodore A Gooley; Leona Holmberg; Gretchen Henstorf; C Fred LeMaistre; Maureen D Mayes; Kevin T McDonagh; Bernadette McLaughlin; Jerry A Molitor; J Lee Nelson; Howard Shulman; Rainer Storb; Federico Viganego; Mark H Wener; James R Seibold; Keith M Sullivan; Daniel E Furst Journal: Blood Date: 2007-04-23 Impact factor: 22.113
Authors: Richard K Burt; Yvonne Loh; Bruce Cohen; Dusan Stefoski; Dusan Stefosky; Roumen Balabanov; George Katsamakis; Yu Oyama; Eric J Russell; Jessica Stern; Paolo Muraro; John Rose; Alessandro Testori; Jurate Bucha; Borko Jovanovic; Francesca Milanetti; Jan Storek; Julio C Voltarelli; William H Burns Journal: Lancet Neurol Date: 2009-01-29 Impact factor: 44.182
Authors: M C Vonk; Z Marjanovic; F H J van den Hoogen; S Zohar; A V M B Schattenberg; W E Fibbe; J Larghero; E Gluckman; F W M B Preijers; A P J van Dijk; J J Bax; P Roblot; P L C M van Riel; J M van Laar; D Farge Journal: Ann Rheum Dis Date: 2007-05-25 Impact factor: 19.103
Authors: Alice R Lorenzi; Alexandra M Clarke; Tom Wooldridge; Herman Waldmann; Geoff Hale; Deborah Symmons; Brian L Hazleman; John D Isaacs Journal: Arthritis Rheum Date: 2008-02
Authors: Keith M Sullivan; Navneet S Majhail; Christopher Bredeson; Paul A Carpenter; Soumya Chatterjee; Leslie J Crofford; George E Georges; Richard A Nash; Marcelo C Pasquini; Stefanie Sarantopoulos; Jan Storek; Bipin Savani; E William St Clair Journal: Biol Blood Marrow Transplant Date: 2018-06-25 Impact factor: 5.742
Authors: G Massenkeil; T Alexander; O Rosen; B Dörken; G Burmester; A Radbruch; F Hiepe; R Arnold Journal: Rheumatol Int Date: 2016-08-13 Impact factor: 2.631
Authors: L C M Arruda; J C C Lorenzi; A P A Sousa; D L Zanette; P V B Palma; R A Panepucci; D S Brum; A A Barreira; D T Covas; B P Simões; W A Silva; M C Oliveira; K C R Malmegrim Journal: Bone Marrow Transplant Date: 2014-12-08 Impact factor: 5.483